Within the kidney, FXR activation downregulates lipogenic and fibrotic genes and reduces diabetes and obesity-related changes including glomerulosclerosis, tubulointerstitial fibrosis and proteinuria [21–26]. The gene discussed is NR1H4; the disease is Obesity.